Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 10/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11511155 | 0.85 | ALDH1A1 (0.69) | ALDH1A1KMT2AKDM4EMEN1LMNA | |
| SCHEMBL14133313 | 0.79 | ALDH1A1 (0.67) | ALDH1A1KMT2AKDM4EMEN1LMNA | |
| SCHEMBL13831408 | 0.78 | POLB (0.65) | ALDH1A1KMT2AKDM4EMEN1GAA | |
| SCHEMBL11510495 | 0.78 | ALDH1A1 (0.73) | ALDH1A1KMT2AKDM4EMEN1LMNA | |
| SCHEMBL18997268 | 0.77 | ALDH1A1 (0.64) | ALDH1A1KMT2AKDM4EMEN1LMNA | |
| SCHEMBL3905153 | 0.76 | TSHR (0.64) | ALDH1A1KMT2AMEN1LMNAPKM | |
| SCHEMBL13401419 | 0.75 | POLB (0.77) | ALDH1A1KMT2AKDM4EMEN1LMNA | |
| SCHEMBL6404149 | 0.75 | ALDH1A1 (0.64) | ALDH1A1KMT2AKDM4EMEN1LMNA | |
| SCHEMBL3904525 | 0.72 | ALDH1A1 (1.00) | ALDH1A1KMT2AKDM4EMEN1LMNA | |
| SCHEMBL31160371 | 0.71 | LMNA (0.53) | ALDH1A1KMT2AMEN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563905-B2 | Triazole derivatives and method of using the same to treat HIV infections | WYETH (US) | 2009-07-21 | — | — | US | claimed |
| WO-2005090320-A2 | TRIAZOLE DERIVATIVES AND METHOD OF USING THE SAME TO TREAT HIV INFECTIONS | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050209287-A1 | Triazole derivatives and method of using the same to treat HIV infections | WYETH | 2005-09-22 | — | — | US | claimed |
| US-7563905-B2 | Triazole derivatives and method of using the same to treat HIV infections | WYETH (US) | 2009-07-21 | — | — | US | disclosed |
| WO-2005090320-A2 | TRIAZOLE DERIVATIVES AND METHOD OF USING THE SAME TO TREAT HIV INFECTIONS | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050209287-A1 | Triazole derivatives and method of using the same to treat HIV infections | WYETH | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209287-A1 | Triazole derivatives and method of using the same to treat HIV infections | CYP3A43, XDH, AKR1C3 | ALDH1A1 430/4885KMT2A 2209/4885KDM4E 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.